DBV Technologies S.A.

DBVT Healthcare Biotechnology

DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024. In the quarter to June 2026, revenue fell 53.3%, EPS grew 61.3% and free cash flow fell 56.2%, each against the same quarter a year earlier.

9.05 0.06 −0.66%
Market cap
$572.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
1.33
Beneish M
n/a
Dividend safety
n/a

DBV Technologies S.A. (DBVT) P/E ratio

Alert me on P/E ratio

DBV Technologies S.A. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
22 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on DBVT